Correlation Between Vaxxinity and Agios Pharm
Can any of the company-specific risk be diversified away by investing in both Vaxxinity and Agios Pharm at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Vaxxinity and Agios Pharm into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Vaxxinity and Agios Pharm, you can compare the effects of market volatilities on Vaxxinity and Agios Pharm and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Vaxxinity with a short position of Agios Pharm. Check out your portfolio center. Please also check ongoing floating volatility patterns of Vaxxinity and Agios Pharm.
Diversification Opportunities for Vaxxinity and Agios Pharm
0.0 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between Vaxxinity and Agios is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Vaxxinity and Agios Pharm in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Agios Pharm and Vaxxinity is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Vaxxinity are associated (or correlated) with Agios Pharm. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Agios Pharm has no effect on the direction of Vaxxinity i.e., Vaxxinity and Agios Pharm go up and down completely randomly.
Pair Corralation between Vaxxinity and Agios Pharm
If you would invest (100.00) in Vaxxinity on December 29, 2024 and sell it today you would earn a total of 100.00 from holding Vaxxinity or generate -100.0% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Flat |
Strength | Insignificant |
Accuracy | 0.0% |
Values | Daily Returns |
Vaxxinity vs. Agios Pharm
Performance |
Timeline |
Vaxxinity |
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Agios Pharm |
Vaxxinity and Agios Pharm Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Vaxxinity and Agios Pharm
The main advantage of trading using opposite Vaxxinity and Agios Pharm positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Vaxxinity position performs unexpectedly, Agios Pharm can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agios Pharm will offset losses from the drop in Agios Pharm's long position.Vaxxinity vs. Tarsus Pharmaceuticals | Vaxxinity vs. Aldeyra | Vaxxinity vs. Travere Therapeutics | Vaxxinity vs. Eton Pharmaceuticals |
Agios Pharm vs. Mereo BioPharma Group | Agios Pharm vs. Blueprint Medicines Corp | Agios Pharm vs. Day One Biopharmaceuticals | Agios Pharm vs. Biomarin Pharmaceutical |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Other Complementary Tools
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |